Antifungal medication improves treatment of sarcoidosis
Completed
- Conditions
- Pulmonary sarcoidosisHaematological DisordersSarcoidosis
- Registration Number
- ISRCTN34533986
- Lead Sponsor
- niversity Hospital, Ljubljana (Slovenia)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Subjects with sarcoidosis diagnosed using established criteria at the Department of Pulmonary and Allergic diseases at the Medical Center, University hospital of Ljubljana, Slovenia.
2. Informed consent
Exclusion Criteria
Severe sarcoidosis requiring immediate treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do antifungal agents modulate Th1/Th17 pathways in pulmonary sarcoidosis treatment?
What is the comparative efficacy of antifungal therapy vs. corticosteroids in ISRCTN34533986?
Which cytokine biomarkers predict response to antifungal treatment in sarcoidosis patients?
What are the safety profiles of antifungal drugs in sarcoidosis, especially hematological toxicity?
How do combination therapies with antifungals and immunosuppressants affect sarcoidosis outcomes?